The era of targeted therapy for hyperlipidemia
Despite a variety of lipid-lowering drugs, mostly pelleted, aimed at reducing low-density lipoprotein cholesterol and triglycerides, only a small number of patients achieve their target levels. The reasons are insufficient adherence to treatment, rare use of combined lipid-lowering therapy regimens...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | ロシア語 |
| 出版事項: |
«FIRMA «SILICEA» LLC
2024-10-01
|
| シリーズ: | Российский кардиологический журнал |
| 主題: | |
| オンライン･アクセス: | https://russjcardiol.elpub.ru/jour/article/view/6038 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
| 要約: | Despite a variety of lipid-lowering drugs, mostly pelleted, aimed at reducing low-density lipoprotein cholesterol and triglycerides, only a small number of patients achieve their target levels. The reasons are insufficient adherence to treatment, rare use of combined lipid-lowering therapy regimens by attending physicians, low availability and high cost of injected lipid-lowering agents. With the advent of technologies for targeted therapy for hyperlipidemia, a new era in cardiology opens. These innovations will lead to higher goal achievement rates through a personalized and precision approach to hyperlipidemia treatment. Novel lipid-lowering drugs are directed at the molecular targets of hypercholesterolemia, hyperlipoproteinemia(a) and hypertriglyceridemia. The review purpose is to systematize following information about innovative lipid-lowering drugs: mechanism of action, stage of development, effectiveness and safety. |
|---|---|
| ISSN: | 1560-4071 2618-7620 |